Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta Cell Function in Type 2 Diabetes in Black Patients
NCT07325435Phase 4Active, not recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: Change in Stimulated C-peptide Index during an Oral Glucose Tolerance Test at 16 weeks. Started Dec 2024; status: active, not recruiting.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07325435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07325435.